06:03 AM EDT, 08/07/2026 (MT Newswires) -- BioInvent International (BINV.ST) received fast track designation from the US Food and Drug Administration for its BI-1808 antibody for the treatment of ovarian cancer in combination with pembrolizumab. The novel immune-modulatory antibodies discovery company said in a Friday release that the treatment combination produced a 24% confirmed overall response rate and a 56% disease control rate in interim phase 2a results.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.